RecruitingPhase 1NCT04516447

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

Sponsor

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Enrollment

172 participants

Start Date

Oct 26, 2020

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Fallopian Tube Cancer Epithelial Ovarian Cancer Peritoneal Cancer

Summary

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing ZN-c3, a new targeted drug, in women with advanced high-grade serous ovarian, fallopian tube, or peritoneal cancer who have already received one or two rounds of prior treatment. **You may be eligible if...** - You have been diagnosed with high-grade serous ovarian, fallopian tube, or peritoneal cancer - You have received 1 or 2 prior treatment regimens for advanced or metastatic disease - Your cancer has measurable tumors on imaging - You are in good enough health to participate **You may NOT be eligible if...** - You have received more than 2 prior lines of treatment for advanced disease - You have active brain metastases - You have significant heart or liver problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAzenosertib

Investigational drug

DRUGCarboplatin

Carboplatin is an approved drug

DRUGPegylated liposomal doxorubicin

Pegylated liposomal doxorubicin (PLD) is an approved drug

DRUGPaclitaxel

Paclitaxel is an approved drug

DRUGGemcitabine

Gemcitabine is an approved drug

BIOLOGICALBevacizumab

Bevacizumab is an approved drug

Locations(24)

Site 0264

Aurora, Colorado, United States

Site 0104

Boston, Massachusetts, United States

Site 0111

St Louis, Missouri, United States

Site 0173

New York, New York, United States

Site 0259

Durham, North Carolina, United States

Site 0191

Providence, Rhode Island, United States

Site 0196

Nashville, Tennessee, United States

Site 0103

Houston, Texas, United States

Site 2707

South Brisbane, Queensland, Australia

Site 2708

Sunshine Coast, Queensland, Australia

Site 2709

Adelaide, South Australia, Australia

Site 2716

Melbourne, Victoria, Australia

Site 2706

Melbourne, Victoria, Australia

Site 2705

Nedlands, Western Australia, Australia

Site 1001

Banja Luka, Bosnia and Herzegovina

Site 1002

Sarajevo, Bosnia and Herzegovina

Site 1003

Tuzla, Bosnia and Herzegovina

Site 1202

Panagyurishte, Bulgaria

Site 1201

Sofia, Bulgaria

Site 1401

Tbilisi, Georgia

Site 1902

Belgrade, Serbia

Site 2901

Busan, South Korea

Site 2903

Seoul, South Korea

Site 2904

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04516447

Related Trials

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467164 locations

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

NCT063498371 location

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT064413315 locations

Study of ZGGS34 in Participants With Advanced Solid Tumors

NCT072581211 location